Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the earnings call transcript. The company has fully utilized its net IPO proceeds of ₹2,072.81 million as of 31 March 2024. The transcript focuses on operational updates, capacity expansion plans, and expected revenue growth but does not indicate plans for additional capital raising. CAPEX for FY25 and FY26 is planned at around ₹70 crores, to be funded from internal accruals, with no equity or debt fundraising mentioned. Soil testing issues have delayed new plant construction but no mention of raising funds

Any current/future capex/capital investment/strategic investment?

Planned CAPEX for FY25 and FY26 is around Rs. 70 crores. CAPEX was delayed due to unfavorable soil test results at the identified site for a multi-story plant. The company is testing three alternative sites; if unsuitable, may scale down plant from 7 floors to 4 floors. The new plant is critical to address capacity constraints expected by FY26. Additional investments include setting up a solvent recovery & distillation plant (commissioning by May-June) and a bromine recovery plant (by August-September). Waste treatment setups are being considered within existing premises to optimize plant util

Future growth expectations in sales/revenue/volumes?

SDA segment volume expected to grow nearly 50% in FY25 with 25% revenue growth due to raw material price reductions; further 30-40% volume growth expected in FY26 driven by Euro 7 implementation. Electrolyte Salts revenue projected to increase by around 150-160% in FY25. PASC segment anticipated to grow 80-90% in FY25, with commercial production started for some products. Phase Transfer Catalysts (PTC) expected to grow 8-10% in FY25 despite price declines. New automotive customers expected to contribute significant volumes, with roughly 15% of their existing business volume expected in FY25; r

Future growth expectations in earnings/operating earnings/profits/EPS?

FY25 topline growth expected: Electrolyte Salts revenue to grow 150-160%, PASC 80-90%, PTC 8-10%, SDA 15-20%. Overall volume growth and capacity utilization to increase, with SDA volume growth around 50% and volume growth expected from new and existing customers. EBITDA margins targeted to improve to 22-24% in FY25 from ~17% in FY24 due to better absorption of fixed overhead costs as volumes rise. Employee costs currently at 14-15% of revenue expected to reduce proportionally as revenue grows. Price reductions in SDAs expected to stabilize by Q2 FY25, enabling margin maintenance. CAP

Current/ Expected Orderbook/ Pending Orders?

Commercial supplies have started with one of the two new automotive catalyst customers; the second is pending REACH registration expected within two months. Deliveries of a couple of hundred tonnes have been made to a new large customer for multiple applications with good off-take, though volumes are currently small compared to existing largest customers. Existing largest customers have approved two new products, expected to increase volumes by approximately 40%-45%, with commercial orders booked and a third application expected to commence deliveries between October and December 2024. V

Tatva Chintan Pharma Chem LtdQ4 FY24Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,743P/E: 80.1Market Cap: ₹4.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2

SDA segment volume expected to grow nearly 50% in FY25 with 25% revenue growth due to raw material price reductions; further 30-40% volume growth expected in FY26 driven by Euro 7 implementation.
Electrolyte Salts revenue projected to increase by around 150-160% in FY25.
PASC segment anticipated to grow 80-90% in FY25, with commercial production started for some products.
Phase Transfer Catalysts (PTC) expected to grow 8-10% in FY25 despite price declines.
New automotive customers expected to contribute significant volumes, with roughly 15% of their existing business volume expected in FY25; relationship build-up may take a couple of years.
Capacity constraints anticipated by end-FY25 with utilization reaching 85-90%; CAPEX of Rs.70 crore planned to expand capacity.
Long-term growth seen from innovative products and new site plant expansion despite some delays due to soil testing.

Margin guidance

Category 1

FY25 topline growth expected: Electrolyte Salts revenue to grow 150-160%, PASC 80-90%, PTC 8-10%, SDA 15-20%.
Overall volume growth and capacity utilization to increase, with SDA volume growth around 50% and volume growth expected from new and existing customers.
EBITDA margins targeted to improve to 22-24% in FY25 from ~17% in FY24 due to better absorption of fixed overhead costs as volumes rise.
Employee costs currently at 14-15% of revenue expected to reduce proportionally as revenue grows.
Price reductions in SDAs expected to stabilize by Q2 FY25, enabling margin maintenance.
CAPEX planned at Rs. 70 crores for FY25 and FY26 to address capacity constraints and enable further growth.
New plant delays due to soil testing issues may slightly impact near-term capacity but alternative sites are being evaluated.
Longer-term optimism for revenue growth beyond FY25 linked to new product commercialization and market expansion, including BS VII opportunity targeting FY26.

See what Tatva Chintan Pharma Chem Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity in the earnings call transcript.
The company has fully utilized its net IPO proceeds of ₹2,072.81 million as of 31 March 2024.
The transcript focuses on operational updates, capacity expansion plans, and expected revenue growth but does not indicate plans for additional capital raising.
CAPEX for FY25 and FY26 is planned at around ₹70 crores, to be funded from internal accruals, with no equity or debt fundraising mentioned.
Soil testing issues have delayed new plant construction but no mention of raising funds to resolve this.
Overall, no new debt or equity fundraising is disclosed for immediate or near-future needs.

Order book

Commercial supplies have started with one of the two new automotive catalyst customers; the second is pending REACH registration expected within two months.
Deliveries of a couple of hundred tonnes have been made to a new large customer for multiple applications with good off-take, though volumes are currently small compared to existing largest customers.
Existing largest customers have approved two new products, expected to increase volumes by approximately 40%-45%, with commercial orders booked and a third application expected to commence deliveries between October and December 2024.
Validation and commercial supplies have started for five pharma/agro intermediary products, with full commercialization expected from September 2024 to early 2025.
Specialties like SDAs expect nearly 50% volume growth in FY25 supported by new and existing customers, although price reductions may constrain revenue growth.
Order buildup and inventory creation have been done for certain products to avoid missing volume opportunities due to capacity constraints.

See what Tatva Chintan Pharma Chem Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Planned CAPEX for FY25 and FY26 is around Rs. 70 crores.
CAPEX was delayed due to unfavorable soil test results at the identified site for a multi-story plant.
The company is testing three alternative sites; if unsuitable, may scale down plant from 7 floors to 4 floors.
The new plant is critical to address capacity constraints expected by FY26.
Additional investments include setting up a solvent recovery & distillation plant (commissioning by May-June) and a bromine recovery plant (by August-September).
Waste treatment setups are being considered within existing premises to optimize plant utilization.
The company aims for a multi-story building with maximum reactors for future growth but is flexible based on soil test outcomes.

Track Tatva Chintan Pharma Chem Ltd — get its next earnings analysis in your feed

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisTatva Chintan Pharma Chem Ltd

Rev 2Mar 1

See where Tatva Chintan Pharma Chem Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Tatva Chintan Pharma Chem Ltd rank in Chemicals & Petrochemicals?

Compare Tatva Chintan Pharma Chem Ltd against every Chemicals & Petrochemicals company (Q4 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →